DARE Daré Bioscience, Inc.
USHealthcareAs of 2026-08-24
Why DARE matters now
Daré Bioscience, Inc. (DARE) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.80 with -2.24% on the session and $12.0M in market capitalization; recent performance reads 1-month -3.56% and YTD +12.44%.
The latest financial table shown here is Q1 2026, with revenue of $152.5K, net income of $-3.0M, and EPS of $-0.21. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -49.2%.
The latest indexable market news headline is "DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $12.00; recent insider activity includes Grossman Jessica D. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
42.91
P/S
17.85
EV/EBITDA
-0.39
DCF Value
$0.18
FCF Yield
-49.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
5.6%
Operating Margin
-1034.4%
Net Margin
-1038.8%
ROE
763.4%
ROA
-43.2%
ROIC
-151.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $152.5K | $-3.0M | $-0.21 |
| Q4 2025 | $1.0M | $-1.4M | $-0.10 |
| FY 2025 | $1.0M | $-13.4M | $-1.20 |
| Q3 2025 | $2.3K | $-3.6M | $-0.28 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$12.00
Target (Median)
$12.00
Target Range
$12.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.02
Daré Bioscience, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market healthcare solutions specifically for women in the United States. Its comprehensive pipeline addresses a broad spectrum of needs within women's health, encompassing contraception, fertility, and both sexual and vaginal well-being. The company's initial commercial offering is XACIATO, a prescription single-dose vaginal gel designed to treat bacterial vaginosis in female patients from 12 years of age. Daré has established a licensing agreement with Organon & Co. and Organon International GmbH to commercialize this product. Beyond its marketed therapy, Daré boasts a robust development portfolio. In advanced clinical stages, it is progressing Ovaprene, a monthly hormone-free vaginal contraceptive, and Sildenafil Cream, a topical formulation of sildenafil intended for vulvar and vaginal application to manage female sexual arousal disorder. Several programs are primed for Phase 1 clinical trials, including DARE-HRT1, an intravaginal ring delivering a combination of bio-identical estradiol and progesterone for vasomotor symptom management in hormone therapy. Also in this category are DARE-VVA1, a vaginally administered tamoxifen formulation targeting vulvar and vaginal atrophy in patients with hormone-receptor-positive breast cancer; DARE-FRT1, an intravaginal ring containing bio-identical progesterone for both preterm birth prevention and broader luteal phase support during in vitro fertilization; and DARE-PTB1, another intravaginal ring also utilizing bio-identical progesterone for preventing preterm birth. At the pre-clinical level, Daré is exploring innovative solutions such as DARE-LARC1, a combination product aimed at reversible contraception. This stage also includes ADARE-204 and ADARE-214, which are injectable etonogestrel formulations intended to provide contraception for 6-month and 12-month periods, respectively, alongside DARE-RH1, a non-hormonal contraceptive approach for both men and women. Daré Bioscience, Inc. maintains its corporate headquarters in San Diego, California.